Analyst Ratings for Prime Medicine
Portfolio Pulse from Benzinga Insights
Prime Medicine (NASDAQ:PRME) has received various analyst ratings in the last quarter, with 2 bullish, 1 somewhat bullish, and 1 indifferent. The average price target is $20.5, representing a significant upside from the current price of $9.32. This average price target is a 2.38% decrease from the previous average of $21.00.
October 09, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Prime Medicine has received mixed analyst ratings, with an average price target of $20.5, indicating a potential upside from the current price.
The mixed analyst ratings indicate differing opinions about the company's future performance. However, the average price target suggests a potential upside, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100